GSK (GSK) said Thursday the UK's Medicines and Healthcare products Regulatory Agency has authorized the use of Blenrep combinations to treat relapsed or refractory multiple myeloma.
Blenrep is now approved for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, GSK said.
The regulator also approved the drug in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy, including lenalidomide, it added.
This authorization marks the first in the world for Blenrep in this treatment setting, the company said.
Price: 35.76, Change: +0.39, Percent Change: +1.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。